In the case of SDPs, in support of the first mechanism is the finding of a reduction in Apo B levels and the particle number of VLDL in the subjects with MAFLD treated for one year with SDPs, including the first evidence of reductions in liver steatosis being produced by phytosterols, which to date had not been previously demonstrated with PE supplementation in clinical studies [30]. This evidence concerns the gene APOB and fatty liver disease.